LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Geron Corp

Fechado

SetorSaúde

1.53 8.51

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.42

Máximo

1.58

Indicadores-chave

By Trading Economics

Rendimento

-10M

-29M

Vendas

788K

48M

EPS

-0.03

Margem de lucro

-60.11

Funcionários

229

EBITDA

-1.1M

-11M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+128.87% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-140M

989M

Abertura anterior

-6.98

Fecho anterior

1.53

Sentimento de Notícias

By Acuity

86%

14%

333 / 351 Ranking em Healthcare

Geron Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mar. de 2026, 19:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Diana Shipping Increases Offer to Acquire Genco -- Update

6 de mar. de 2026, 17:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 de mar. de 2026, 22:26 UTC

Notícias Principais

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 de mar. de 2026, 22:03 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

6 de mar. de 2026, 22:03 UTC

Conversa de Mercado

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 de mar. de 2026, 21:50 UTC

Conversa de Mercado
Notícias Principais

Financial Services Roundup: Market Talk

6 de mar. de 2026, 21:37 UTC

Ganhos

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 de mar. de 2026, 21:25 UTC

Notícias Principais

How The Iran War Impacts Ukraine. -- Barrons.com

6 de mar. de 2026, 21:17 UTC

Ganhos

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 de mar. de 2026, 20:50 UTC

Ganhos

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 de mar. de 2026, 20:46 UTC

Ganhos

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 de mar. de 2026, 20:31 UTC

Notícias Principais

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 de mar. de 2026, 20:18 UTC

Conversa de Mercado

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 de mar. de 2026, 20:12 UTC

Conversa de Mercado
Notícias Principais

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 de mar. de 2026, 19:10 UTC

Conversa de Mercado
Notícias Principais

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 de mar. de 2026, 18:54 UTC

Conversa de Mercado

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 de mar. de 2026, 18:44 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 de mar. de 2026, 18:08 UTC

Ganhos

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 de mar. de 2026, 18:04 UTC

Ganhos

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 de mar. de 2026, 18:04 UTC

Ganhos

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 de mar. de 2026, 17:49 UTC

Conversa de Mercado

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 de mar. de 2026, 17:46 UTC

Notícias Principais

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 de mar. de 2026, 17:40 UTC

Conversa de Mercado
Ganhos

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 de mar. de 2026, 17:40 UTC

Ganhos

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 de mar. de 2026, 17:32 UTC

Conversa de Mercado
Notícias Principais

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 de mar. de 2026, 17:28 UTC

Conversa de Mercado
Notícias Principais

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 de mar. de 2026, 17:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

6 de mar. de 2026, 17:20 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

6 de mar. de 2026, 17:20 UTC

Aquisições, Fusões, Aquisições de Empresas

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Comparação entre Pares

Variação de preço

Geron Corp Previsão

Preço-alvo

By TipRanks

128.87% parte superior

Previsão para 12 meses

Média 3.25 USD  128.87%

Máximo 5 USD

Mínimo 1 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Geron Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

3

Comprar

1

Manter

1

Vender

Sentimento

By Acuity

333 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat